title: Cisplatin and 5-fluorouracil in refractory breast cancer patients: a phase II study.
abstract: 24 patients with a median of 3 prior chemotherapy regimens were treated in our department with cisplatin 20 mg/m2 (with pre- and posthydration) and 5-fluorouracil 200 mg/m2 i.v. on day 1-5, every three weeks. 23 patients are evaluable; one had early death. 4 patients (17%) achieved a partial response, 8 had stable disease, and 11 progressed. Toxicity observed was moderate and no renal toxicity was noted. This study therefore shows tolerable toxicity but limited usefulness of adding cisplatin to 5-fluorouracil according to this schedule in these highly pretreated patients.
authors.affiliation: Istituto Nazionale per la Ricerca sul Cancro, Divisione di Oncologia Medica, Genova, Italy.
authors.forename: D
authors.initials: D
authors.lastname: Amoroso
authors.forename: P
authors.initials: P
authors.lastname: Pronzato
authors.forename: G
authors.initials: G
authors.lastname: Bertelli
authors.forename: P
authors.initials: P
authors.lastname: Gallotti
authors.forename: G
authors.initials: G
authors.lastname: Pastorino
authors.forename: M P
authors.initials: MP
authors.lastname: Cusimano
authors.forename: M
authors.initials: M
authors.lastname: Merlano
authors.forename: P F
authors.initials: PF
authors.lastname: Conte
authors.forename: R
authors.initials: R
authors.lastname: Rosso
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D002945:Cisplatin / Q000008:administration & dosage*; D004341:Drug Evaluation; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage*; D006801:Humans; D008875:Middle Aged
chemical_list: D002945:Cisplatin; D005472:Fluorouracil